KR20220109401A - Parp7 억제제로서의 피리다진온 - Google Patents

Parp7 억제제로서의 피리다진온 Download PDF

Info

Publication number
KR20220109401A
KR20220109401A KR1020227018075A KR20227018075A KR20220109401A KR 20220109401 A KR20220109401 A KR 20220109401A KR 1020227018075 A KR1020227018075 A KR 1020227018075A KR 20227018075 A KR20227018075 A KR 20227018075A KR 20220109401 A KR20220109401 A KR 20220109401A
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
alkyl
piperidin
oxy
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018075A
Other languages
English (en)
Korean (ko)
Inventor
니콜라스 로버트 펄
멜리사 마리 바스빈더
케빈 웨인 쿤츠
Original Assignee
리본 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리본 테라퓨틱스 인코포레이티드 filed Critical 리본 테라퓨틱스 인코포레이티드
Publication of KR20220109401A publication Critical patent/KR20220109401A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227018075A 2019-10-30 2020-10-29 Parp7 억제제로서의 피리다진온 Pending KR20220109401A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927934P 2019-10-30 2019-10-30
US62/927,934 2019-10-30
PCT/US2020/057831 WO2021087025A1 (en) 2019-10-30 2020-10-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
KR20220109401A true KR20220109401A (ko) 2022-08-04

Family

ID=73699388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018075A Pending KR20220109401A (ko) 2019-10-30 2020-10-29 Parp7 억제제로서의 피리다진온

Country Status (13)

Country Link
US (1) US11691969B2 (https=)
EP (1) EP4051384A1 (https=)
JP (1) JP7641957B2 (https=)
KR (1) KR20220109401A (https=)
CN (1) CN114761086B (https=)
AR (1) AR120338A1 (https=)
AU (1) AU2020375821B2 (https=)
CA (1) CA3159188A1 (https=)
IL (1) IL292432A (https=)
MX (1) MX2022005216A (https=)
PH (1) PH12022551013A1 (https=)
TW (1) TWI902715B (https=)
WO (1) WO2021087025A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN116157396B (zh) * 2020-11-27 2025-07-18 康百达（四川）生物医药科技有限公司 哒嗪酮衍生物及其在医药上的应用
CN116724044B (zh) * 2021-02-03 2025-10-31 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
JP2024506612A (ja) * 2021-02-09 2024-02-14 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｐａｒｐ７阻害剤として有用な三環式誘導体
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
KR20240012534A (ko) * 2021-05-21 2024-01-29 청두 바이위 파머수티컬 씨오., 엘티디 피페라진 유도체 및 이의 의학적 용도
CN117396485B (zh) * 2021-05-25 2026-01-30 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CN117377665B (zh) * 2021-08-16 2026-04-21 重庆华森英诺生物科技有限公司 Parp7抑制剂及其应用
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116444497B (zh) * 2022-01-14 2025-06-24 如东凌达生物医药科技有限公司 一类哒嗪酮类化合物、制备及其应用
TW202340168A (zh) * 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
JP7763538B2 (ja) * 2022-04-01 2025-11-04 諾沃斯達薬業（上海）有限公司 Ｐａｒｐ７阻害剤及びその使用
CN117586263B (zh) * 2022-08-09 2026-04-10 康百达（四川）生物医药科技有限公司 哌嗪衍生物及其在医药上的应用
WO2024037558A1 (en) * 2022-08-17 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. Solid forms of compound i or salts thereof
CN117164524B (zh) * 2022-09-06 2026-02-03 杭州师范大学 具有parp7/hdac双靶点抑制活性的哒嗪酮衍生物及其制备方法和应用
CN120917010A (zh) * 2023-01-10 2025-11-07 嘉兴和剂药业有限公司 Parp7抑制剂及其用途
CN118388414A (zh) * 2023-01-17 2024-07-26 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2025045134A1 (zh) * 2023-08-29 2025-03-06 康百达（四川）生物医药科技有限公司 一种哌嗪衍生物的制备工艺及其中间体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157602C (zh) 1997-09-05 2004-07-14 松下电器产业株式会社 荧光偏振法检测样品的方法及其中使用的试剂
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
CN101981013B (zh) 2008-03-27 2013-05-29 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US20240190844A1 (en) 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
EP4051384A1 (en) 2022-09-07
US20240034728A1 (en) 2024-02-01
AU2020375821B2 (en) 2026-03-19
IL292432A (en) 2022-06-01
US11691969B2 (en) 2023-07-04
AR120338A1 (es) 2022-02-09
CN114761086A (zh) 2022-07-15
PH12022551013A1 (en) 2023-03-06
JP7641957B2 (ja) 2025-03-07
TW202128653A (zh) 2021-08-01
US20210130342A1 (en) 2021-05-06
TWI902715B (zh) 2025-11-01
AU2020375821A1 (en) 2022-06-02
CN114761086B (zh) 2025-07-22
CA3159188A1 (en) 2021-05-06
JP2023501253A (ja) 2023-01-18
WO2021087025A1 (en) 2021-05-06
MX2022005216A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7641957B2 (ja) Ｐａｒｐ７阻害剤としてのピリダジノン
AU2024200566B2 (en) Pyridazinones as PARP7 inhibitors
US20250074897A1 (en) Pyridazinones as parp7 inhibitors
KR20220102156A (ko) Bcl6 표적화 모이어티에 연결된 e3 유비퀴틴 리가아제 결합 모이어티를 함유하는 이기능성 분자
CA3176957A1 (en) Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
US12617782B2 (en) Pyridazinones as PARP7 inhibitors
EA049968B1 (ru) Пиридазиноны как ингибиторы parp7
HK40048232A (en) Pyridazinones as parp7 inhibitors
HK40048232B (en) Pyridazinones as parp7 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902